DRUG

Flubendazole

9 hypotheses across 5 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

Flubendazole appears in hypotheses across 5 disease domains: ALS, Alzheimer, Epilepsy, Pancreatic cancer, Rheumatoid arthritis. Shared mediators that recur across at least two of those domains: STAT3.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for Flubendazole

ALS 1

Mediator Outcome Score Tier Lit. status Trial
STAT3 muscle atrophy 0.208 Mid novel signal none

Alzheimer 1

Mediator Outcome Score Tier Lit. status Trial
STAT3 Alzheimer's disease 0.208 Mid partial evidence none

Epilepsy 4

Mediator Outcome Score Tier Lit. status Trial
STAT3 imprinting of epileptic activity patterns 0.208 Mid novel signal none
STAT3 GABAergic neuron loss 0.208 Mid novel signal none
STAT3 general cell loss 0.208 Mid novel signal none
STAT3 persistence of reactive glial states 0.208 Mid novel signal none

Pancreatic cancer 2

Mediator Outcome Score Tier Lit. status Trial
STAT3 pancreatic cancer 0.208 Mid partial evidence none
STAT3 drug resistance 0.208 Mid reproduces known none

Rheumatoid arthritis 1

Mediator Outcome Score Tier Lit. status Trial
STAT3 prurigo nodularis 0.312 High novel signal none

Clinical trials

1 registered trial for Flubendazole

Source: ClinicalTrials.gov

← All drugs